A. Rider

pfizer usa

H指数:14

被引数:777

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment Experience of Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in a Real-World Setting: European Patients' Perspectives

早期激素受体阳性、人表皮生长因子受体2阴性乳腺癌在真实世界中的治疗经验：欧洲患者的视角

BREAST CARE

IF0

2025-09-010

PRE

An Exploration Of Treatments For Platinum-Ineligible Ovarian Cancer: Analysis Of The Adelphi Real World Disease Specific Programme (DSP™)

对铂类不敏感卵巢癌治疗的探索：Adelphi真实世界疾病专项计划（DSP™）的分析

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

IF4.7

2025-02-010

PRE

Real-world clinical profile, RET mutation testing, treatments and patient-related outcomes for medullary thyroid cancer in Europe

EUROPEAN THYROID JOURNAL

IF4.3

2024-01-080

OAAI

Real-world clinical profile, treatment patterns and patient-reported outcomes for thyroid cancer in Japan

FUTURE ONCOLOGY

IF2.6

2023-06-060

Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel

BMC CANCER

IF3.4

2022-12-222

OAAI

Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel

BREAST

IF7.9

2022-12-012

OAAI

Physician- and patient-reported symptom concordance and association with quality of life in hepatocellular carcinoma

FUTURE ONCOLOGY

IF2.6

2022-11-152

Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel

ADVANCES IN THERAPY

IF4

2022-10-288

OAAI

Management of early-stage hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a real-word setting in Germany: A patient perspective

ANNALS OF ONCOLOGY

IF65.4

2022-05-010

Patient profiles, management and treatment patterns in HR+, HER2-early breast cancer in a real-world setting in Spain

CANCER RESEARCH

IF16.6

2022-02-150

PRE

Real-world multi-country study of BRCA1/2 mutation testing among adult women with HER2-negative advanced breast cancer

在HER2-negative晚期乳腺癌成年女性中进行BRCA1/2突变检测的真实世界多国研究

FUTURE ONCOLOGY

IF2.6

2022-01-313

Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe

BONE

IF3.6

2022-01-018

OAAI

The relationship between employment status, work productivity and activity impairment (WPAI) and health-related quality of life (HRQoL) for patients (pts) with HR+/HER2-early stage breast cancer (BC)

ANNALS OF ONCOLOGY

IF65.4

2021-09-010

OAAI

REarranged during Transfection [RET] gene fusion testing patterns for patients [pts] with papillary thyroid cancer [PTC] across five European countries

ANNALS OF ONCOLOGY

IF65.4

2021-09-010

OAAI

Characteristics and treatment [tx] patterns in patients [pts] with medullary thyroid cancer [MTC] with and without REarranged during Transfection [RET] mutations in Europe

ANNALS OF ONCOLOGY

IF65.4

2021-09-010

Receipt of neoadjuvant treatment (NADJ) and impact of types of surgery on health-related quality of life (HRQoL) among patients (pts) with early stage HR+/HER2-breast cancer (BC)

ANNALS OF ONCOLOGY

IF65.4

2021-09-010

OAAI

Real-world study of REarranged during Transfection [RET] testing in patients [pts] with medullary thyroid cancer [MTC] in Europe [EU5]

欧洲 [EU5] 甲状腺髓样癌 [MTC] 患者 [pts] 转染 [RET] 测试期间重排的真实世界研究

ANNALS OF ONCOLOGY

IF65.4

2021-09-011

OAAI

Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2-advanced breast cancer patients with poor prognostic factors: data from an international study

ESMO OPEN

IF8.3

2021-08-014

OAAI

Reliability, validity and important difference estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18)

FUTURE ONCOLOGY

IF2.6

2021-07-212

PREAI

HR /HER2-Early乳腺癌患者的健康相关生活质量

CLINICAL THERAPEUTICS

IF3.6

2021-07-0113

PREAI

A. Rider

个人简介

教育背景

工作经历

荣誉奖项

研究方向